한글목차

세계의 C-MET 및 HGF 저해제 시장 규모는 2024년에 34억 8,000만 달러로 추정되며, 2025-2031년의 예측 기간에 CAGR 17.5%로 성장하며, 2031년까지 107억 1,300만 달러로 확대할 것으로 예측되고 있습니다.

이 보고서는 C-MET & HGF 억제제에 대한 최근 관세 조정 및 국제적인 전략적 대응 조치에 대해 국경 간 산업적 발자취, 자본 배분 패턴, 지역 경제의 상호의존성, 공급망 재구축을 종합적으로 평가합니다.

C-MET 및 HGF 억제제는 간세포증식인자(HGF)와 그 수용체인 c-MET 신호전달 경로의 비정상적인 활성화를 억제하도록 설계된 표적치료제의 일종입니다. 이 경로는 특히 간세포암, 폐암, 위암, 신장암 등의 암에서 증식, 침윤, 혈관신생, 전이와 같은 종양 형성 과정에 관여합니다. 이 억제제에는 저분자 티로신 키나아제 억제제(TKI)와 단일 클론 항체가 포함됩니다. 최근 수년간, 이들은 종양학에서 의약품 개발의 주요 초점이 되고 있습니다. FDA 승인 약물인 캡마티닙, 테포티닙 등의 약물은 입증된 임상적 유효성과 안전성으로 시장 확대를 가속화하고 있습니다. 2024년 세계 C-MET & HGF 억제제 생산량은 약 2,400만 단위, 세계 평균 시장 가격은 단위당 약 145달러에 달했습니다.

여러 악성 종양에서 c-MET/HGF 신호전달 경로의 비정상적인 활성화 또는 과발현은 정밀 종양학에서 명확한 표적을 제공합니다. 화이자와 노바티스의 연례 보고서에서 알 수 있듯이, 승인된 C-MET 억제제 중 일부는 특히 진행성 비소세포폐암에서 빠른 상용화를 달성하고 있습니다. 전 세계 종양학 시장의 확대와 개인 맞춤형 치료 프로토콜의 채택이 증가함에 따라 C-MET & HGF 억제제는 적응증 확대에 있으며, 큰 잠재력을 가지고 있습니다. RNA 시퀀싱과 같은 분자진단 기술의 보급으로 C-MET 양성 환자의 식별이 더욱 가속화되어 치료의 보급이 촉진되고 있습니다.

유망한 임상 결과에도 불구하고 C-MET 및 HGF 억제제는 효과의 편차, 복잡한 내성 기전, 부작용 관리 등의 문제에 직면해 있습니다. 일부 초기 후보물질은 표준화된 바이오마커에 기반한 환자 선택이 부족하여 임상 3상 시험에서 실망스러운 결과를 얻거나 좌절을 경험한 바 있습니다. 전 세계에서 안전성과 유효성에 대한 확실한 실제 임상 데이터를 요구하는 규제 압력이 증가하고 있으며, 개발 기간과 비용이 증가하고 있습니다.

정밀 표적 치료의 임상적 수용이 진행되면서 C-MET 억제제가 다제 병용 요법에 포함되고 있습니다. IQVIA 및 FDA 데이터에 따르면 C-MET 억제제와 면역관문억제제 병용요법을 검증하는 다수의 세계 임상시험이 진행 중입니다. 중국, 한국 및 기타 시장의 경우, 상환 정책의 개선과 현지 바이오텍 기업의 부상으로 인해 향후 수년간 시장 침투가 크게 가속화될 것으로 예측됩니다.

이 보고서는 C-MET & HGF 억제제 세계 시장에 대해 총판매량, 판매 매출, 가격, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목표로 합니다.

이 보고서는 C-MET & HGF 억제제 시장 규모, 추정 및 예측을 판매량(천 단위) 및 매출액(백만 달러)으로 제시하고, 2024년을 기준 연도로 하여 2020-2031년의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적, 정성적 분석을 통해 독자들이 C-MET 및 HGF 억제제 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 지원합니다.

시장 세분화

기업별

• Exelixis
• Ipsen
• Pfizer
• Novartis
• Takeda
• Merck KGaA
• Takeda Pharmaceutical

유형별 부문

• Cabozantinib
• Crizotinib
• Tepotinib
• 기타

용도별 부문

• 병원
• 약국

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동 및 아프리카

영문목차

The global market for C-MET & HGF Inhibitors was estimated to be worth US$ 3480 million in 2024 and is forecast to a readjusted size of US$ 10713 million by 2031 with a CAGR of 17.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on C-MET & HGF Inhibitors cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

C-MET & HGF inhibitors are a class of targeted therapies designed to inhibit the aberrant activation of the hepatocyte growth factor (HGF) and its receptor c-MET signaling pathway. This axis is implicated in tumorigenesis processes such as proliferation, invasion, angiogenesis, and metastasis, especially in cancers such as hepatocellular carcinoma, lung cancer, gastric cancer, and renal cancer. The inhibitors include small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. In recent years, they have become a key focus in oncology drug development. Drugs such as Capmatinib and Tepotinib, approved by the FDA, are accelerating market expansion with demonstrated clinical efficacy and safety. In 2024, global C-MET & HGF Inhibitors production reached approximately 24 million unit, with an average global market price of around US$ 145/unit.

The abnormal activation or overexpression of the c-MET/HGF signaling pathway in multiple malignancies provides a clear target for precision oncology. As revealed in annual reports from Pfizer and Novartis, several approved C-MET inhibitors have achieved rapid commercialization, especially in late-stage NSCLC. With the expanding global oncology market and increasing adoption of individualized treatment protocols, C-MET & HGF inhibitors possess significant potential for indication expansion. The growing availability of molecular diagnostics, such as RNA sequencing, further accelerates the identification of C-MET-positive patients, boosting treatment penetration.

Despite promising clinical outcomes, C-MET & HGF inhibitors face challenges including inconsistent efficacy, complex resistance mechanisms, and adverse event management. Some early candidates have underperformed in Phase III trials or faced setbacks due to the lack of standardized biomarker-based patient selection. Regulatory pressures are mounting worldwide, demanding robust real-world evidence for safety and efficacy, thus increasing development timelines and costs.

There is growing clinical acceptance of precision-targeted therapies, integrating C-MET inhibitors into multi-line treatment regimens. According to IQVIA and FDA data, numerous global clinical trials are exploring combination therapies involving C-MET inhibitors and immune checkpoint inhibitors. In China, Korea, and other markets, reimbursement policy improvements and the rise of local biotech players are expected to significantly accelerate market penetration in the coming years.

This report aims to provide a comprehensive presentation of the global market for C-MET & HGF Inhibitors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of C-MET & HGF Inhibitors by region & country, by Type, and by Application.

The C-MET & HGF Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding C-MET & HGF Inhibitors.

Market Segmentation

By Company

• Exelixis
• Ipsen
• Pfizer
• Novartis
• Takeda
• Merck KGaA
• Takeda Pharmaceutical

Segment by Type

• Cabozantinib
• Crizotinib
• Tepotinib
• Others

Segment by Application

• Hospital
• Drug Store

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of C-MET & HGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of C-MET & HGF Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 C-MET & HGF Inhibitors Product Introduction
• 1.2 Global C-MET & HGF Inhibitors Market Size Forecast
  • 1.2.1 Global C-MET & HGF Inhibitors Sales Value (2020-2031)
  • 1.2.2 Global C-MET & HGF Inhibitors Sales Volume (2020-2031)
  • 1.2.3 Global C-MET & HGF Inhibitors Sales Price (2020-2031)
• 1.3 C-MET & HGF Inhibitors Market Trends & Drivers
  • 1.3.1 C-MET & HGF Inhibitors Industry Trends
  • 1.3.2 C-MET & HGF Inhibitors Market Drivers & Opportunity
  • 1.3.3 C-MET & HGF Inhibitors Market Challenges
  • 1.3.4 C-MET & HGF Inhibitors Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global C-MET & HGF Inhibitors Players Revenue Ranking (2024)
• 2.2 Global C-MET & HGF Inhibitors Revenue by Company (2020-2025)
• 2.3 Global C-MET & HGF Inhibitors Players Sales Volume Ranking (2024)
• 2.4 Global C-MET & HGF Inhibitors Sales Volume by Company Players (2020-2025)
• 2.5 Global C-MET & HGF Inhibitors Average Price by Company (2020-2025)
• 2.6 Key Manufacturers C-MET & HGF Inhibitors Manufacturing Base and Headquarters
• 2.7 Key Manufacturers C-MET & HGF Inhibitors Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of C-MET & HGF Inhibitors
• 2.9 C-MET & HGF Inhibitors Market Competitive Analysis
  • 2.9.1 C-MET & HGF Inhibitors Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by C-MET & HGF Inhibitors Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in C-MET & HGF Inhibitors as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Cabozantinib
  • 3.1.2 Crizotinib
  • 3.1.3 Tepotinib
  • 3.1.4 Others
• 3.2 Global C-MET & HGF Inhibitors Sales Value by Type
  • 3.2.1 Global C-MET & HGF Inhibitors Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global C-MET & HGF Inhibitors Sales Value, by Type (2020-2031)
  • 3.2.3 Global C-MET & HGF Inhibitors Sales Value, by Type (%) (2020-2031)
• 3.3 Global C-MET & HGF Inhibitors Sales Volume by Type
  • 3.3.1 Global C-MET & HGF Inhibitors Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global C-MET & HGF Inhibitors Sales Volume, by Type (2020-2031)
  • 3.3.3 Global C-MET & HGF Inhibitors Sales Volume, by Type (%) (2020-2031)
• 3.4 Global C-MET & HGF Inhibitors Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hospital
  • 4.1.2 Drug Store
• 4.2 Global C-MET & HGF Inhibitors Sales Value by Application
  • 4.2.1 Global C-MET & HGF Inhibitors Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global C-MET & HGF Inhibitors Sales Value, by Application (2020-2031)
  • 4.2.3 Global C-MET & HGF Inhibitors Sales Value, by Application (%) (2020-2031)
• 4.3 Global C-MET & HGF Inhibitors Sales Volume by Application
  • 4.3.1 Global C-MET & HGF Inhibitors Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global C-MET & HGF Inhibitors Sales Volume, by Application (2020-2031)
  • 4.3.3 Global C-MET & HGF Inhibitors Sales Volume, by Application (%) (2020-2031)
• 4.4 Global C-MET & HGF Inhibitors Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global C-MET & HGF Inhibitors Sales Value by Region
  • 5.1.1 Global C-MET & HGF Inhibitors Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global C-MET & HGF Inhibitors Sales Value by Region (2020-2025)
  • 5.1.3 Global C-MET & HGF Inhibitors Sales Value by Region (2026-2031)
  • 5.1.4 Global C-MET & HGF Inhibitors Sales Value by Region (%), (2020-2031)
• 5.2 Global C-MET & HGF Inhibitors Sales Volume by Region
  • 5.2.1 Global C-MET & HGF Inhibitors Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global C-MET & HGF Inhibitors Sales Volume by Region (2020-2025)
  • 5.2.3 Global C-MET & HGF Inhibitors Sales Volume by Region (2026-2031)
  • 5.2.4 Global C-MET & HGF Inhibitors Sales Volume by Region (%), (2020-2031)
• 5.3 Global C-MET & HGF Inhibitors Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.4.2 North America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.5.2 Europe C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.6.2 Asia Pacific C-MET & HGF Inhibitors Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.7.2 South America C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa C-MET & HGF Inhibitors Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions C-MET & HGF Inhibitors Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions C-MET & HGF Inhibitors Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions C-MET & HGF Inhibitors Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.3.2 United States C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.4.2 Europe C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.5.2 China C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.6.2 Japan C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.7.2 South Korea C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.8.2 Southeast Asia C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India C-MET & HGF Inhibitors Sales Value, 2020-2031
  • 6.9.2 India C-MET & HGF Inhibitors Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India C-MET & HGF Inhibitors Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Exelixis
  • 7.1.1 Exelixis Company Information
  • 7.1.2 Exelixis Introduction and Business Overview
  • 7.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Exelixis C-MET & HGF Inhibitors Product Offerings
  • 7.1.5 Exelixis Recent Development
• 7.2 Ipsen
  • 7.2.1 Ipsen Company Information
  • 7.2.2 Ipsen Introduction and Business Overview
  • 7.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Ipsen C-MET & HGF Inhibitors Product Offerings
  • 7.2.5 Ipsen Recent Development
• 7.3 Pfizer
  • 7.3.1 Pfizer Company Information
  • 7.3.2 Pfizer Introduction and Business Overview
  • 7.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Pfizer C-MET & HGF Inhibitors Product Offerings
  • 7.3.5 Pfizer Recent Development
• 7.4 Novartis
  • 7.4.1 Novartis Company Information
  • 7.4.2 Novartis Introduction and Business Overview
  • 7.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Novartis C-MET & HGF Inhibitors Product Offerings
  • 7.4.5 Novartis Recent Development
• 7.5 Takeda
  • 7.5.1 Takeda Company Information
  • 7.5.2 Takeda Introduction and Business Overview
  • 7.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Takeda C-MET & HGF Inhibitors Product Offerings
  • 7.5.5 Takeda Recent Development
• 7.6 Merck KGaA
  • 7.6.1 Merck KGaA Company Information
  • 7.6.2 Merck KGaA Introduction and Business Overview
  • 7.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Merck KGaA C-MET & HGF Inhibitors Product Offerings
  • 7.6.5 Merck KGaA Recent Development
• 7.7 Takeda Pharmaceutical
  • 7.7.1 Takeda Pharmaceutical Company Information
  • 7.7.2 Takeda Pharmaceutical Introduction and Business Overview
  • 7.7.3 Takeda Pharmaceutical C-MET & HGF Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Takeda Pharmaceutical C-MET & HGF Inhibitors Product Offerings
  • 7.7.5 Takeda Pharmaceutical Recent Development

8 Industry Chain Analysis

• 8.1 C-MET & HGF Inhibitors Industrial Chain
• 8.2 C-MET & HGF Inhibitors Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 C-MET & HGF Inhibitors Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 C-MET & HGF Inhibitors Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer